Tolerx Inc. has enrolled its first patient in a late-stage clinical trial for a potential therapy to treat type 1 — juvenile — diabetes. If the drug is later approved, it would be the first one-time therapy for the disease, which currently requires continuous management of blood glucose levels.
The Cambridge-based biotechnology company plans to enroll up to 365 patients, age 12 to 45, with newly diagnosed autoimmune type 1 diabetes. The trial is being conducted at more than 200 sites in North America and Europe. This is the second of two Phase 3 trials to be conducted on the drug target.